|
Haplotype distribution in colorectal cancer patients and normal controls |
||||||
| Haplotype |
Frequecy |
Distribution |
Healthy control (N = 568) |
CRC patients (N = 436) |
p |
OR(95% CI) |
|
|
||||||
| HT1 (G-T-G) |
0.511 |
non-HT1/non-HT1 |
140 (24.6%) |
99 (22.7%) |
0.336 |
1.160 (0.857–1.571) |
| HT1/non-HT1 or HT1/HT1 |
428 (75.4%) |
337 (77.3%) |
||||
| HT2 (A-T-G) |
0.422 |
non-HT2/non-HT2 |
204 (35.9%) |
127 (29.1%) |
0.021 |
1.386 (1.052–1.828) |
| HT2/non-HT2 or HT2/HT2 |
364 (64.1%) |
309 (70.9%) |
||||
| HT3 (G-C-G) |
0.033 |
non-HT3/non-HT3 |
532 (93.7%) |
405 (92.9%) |
0.984 |
0.995 (0.595–1.663) |
| HT3/non-HT3 |
36 (6.3%) |
31 (7.1) |
||||
| HT4 (G-C-A) |
0.032 |
non-HT4/non-HT4 |
522 (91.9%) |
416 (95.4%) |
0.032 |
0.539 (0.307–0.947) |
| HT4/non-HT4 |
46 (8.1%) |
20 (4.6%) |
||||
|
Adjusted for age and sex; Non-HT1 includes HT2, HT3 and HT4 but not HT1. Dominant model | ||||||
Jang et al. BMC Cancer 2007 7:16 doi:10.1186/1471-2407-7-16 |
||||||